Momentum has been building for legislators to address Medicare’s broken home infusion benefit as part of a year-end legislative package. After considerable engagement from NHIA, the groundwork has been laid for Congress to pass the Preserving Patient Access to Home Infusion Act (H.R. 4104; S. 1976) and enhance access to home infusion services for Medicare beneficiaries nationwide.
We urge all NHIA members to take action by contacting their Members of Congress and urging them to support policies that promote access to home infusion therapy within the Medicare program.
To facilitate your outreach, we have drafted a sample letter to communicate the need for action to your Representatives and Senators. Your advocacy is critical in advancing this important cause and ensuring that patients receive the care they deserve.
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, are pleased to announce the addition of Melinta to NHIA’s Future of Infusion Advisory Council (FIAC).
A diverse group of more than 35 patient and stakeholder groups are calling on Congress to address Medicare beneficiary access to home infusion services. In a letter to lawmakers, which brings together stakeholders from across the care continuum, the groups urge congressional leaders to advance the Preserving Patient Access to Home Infusion Act (S. 1976/H.R. 4104) and increase access to home infusion therapy for Medicare beneficiaries.
The National Home Infusion Association (NHIA) has developed a list of medications to serve as a reference when making site of care decisions for patients requiring intravenous (IV) or subcutaneous (SC) infusions. The list of medications reflects current U.S. prescribing practices and was compiled from home infusion providers medication dispensing reports and reviewed by NHIA’s Quality and Standards Committee.
